Modulation of activity of proneurotrophins

Patent metadata

Field	Value
Publication number	US-9234036-B2
Application number	US-201414262398-A
Country	US
Kind code	B2
Filing date	Apr 25, 2014
Priority date	Dec 21, 2006
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.

First claim

The invention claimed is:

1. A method of treating pain comprising administering to a subject in need thereof a therapeutically effective amount of an antibody that binds to:
(1) residues 7-10 (RIFR) (SEQ ID NO:27);
(2) residues 14-18 (FAKNF) (SEQ ID NO:28); or
(3) residues 7-10 (RIFR) (SEQ ID NO:27) and residues 14-18 (FAKNF) (SEQ ID NO:28);
of a Sortilin receptor that consists of the amino acid sequence of SEQ ID NO:25, wherein said pain is selected from the group consisting of cutaneous pain, somatic pain, visceral pain and phantom limb pain.

2. The method of claim 1 , wherein said pain is caused by trauma.

3. The method of claim 1 , wherein said pain is caused by a burn.

4. The method of claim 1 , wherein said subject suffers from dysfunction of a kidney, pancreas or lung.

5. The method of claim 1 , wherein said subject suffers from injury of a kidney, pancreas or lung.

6. The method of claim 1 , wherein said subject suffers from diabetes.

7. The method of claim 1 , wherein said pain is cutaneous pain.

8. The method of claim 1 , wherein said pain is somatic pain.

9. The method of claim 1 , wherein said pain is visceral pain.

10. The method of claim 1 , wherein said pain is phantom limb pain.

11. The method of claim 1 , wherein said subject is a human being.

12. The method of claim 1 , wherein said antibody is administered in an amount of from about 1 μg/kg to about 100 mg/kg per day.

13. The method of claim 1 , wherein said antibody is used in combination with a second active ingredient.

Assignees

• Lundbeck & Co As H

Inventors

• Anderson Olav Michael
• Nykjaer Anders

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K16/2863 Primary

  against receptors for growth factors, growth regulators · CPC title

• A61K38/07

  Tetrapeptides · CPC title

• C07K14/70571

  for neuromediators, e.g. serotonin receptor, dopamine receptor · CPC title

• C07K5/1019

  with the first amino acid being basic · CPC title